Compound classes

LYO-X has a unique specialisation in Biotherapeutics

Do you have a novel format and mode of action?
We’d love to work with you to elucidate its PK/PD relationship.

Antibodies

For antibodies target binding can have significant impact on the pharmacokinetics which in turn will drive the pharmacodynamics. This can result in a non-linear PK/PD relationship for example for receptor targets where receptor internalisation can lead to target mediated drug disposition (TMDD). TMDD has to be consider early as rapid drug clearance can inhibit a reasonable treatment interval for most indications

 

Bi-specifics

Bi-specifics can be used to modulate the biological system in various ways. In many cases the resulting PK/PD relationship is complex and non-intuitive. As a consequence typical approaches for antibody design, selection and assays can not be applied for bi-specifics. For example, bi-specifics for cross-linking receptors to induce a pharmacological effect can have a bi-phasic concentration response curve. This has major implications on the design and dose selection for in vitro and in vivo efficacy and toxicity studies.
We use Systems Pharmacology to model the binding between a bi-specific and its target in a PK/PD context to help understand the concentration-effect relationship and identify the important parameters for designing and selecting efficacious candidates. Further, the models are used to design robust and conclusive preclinical and clinical studies. 

 

Antibody-Drug Conjugates (ADCs)

ADCs deliver a toxic payload to target cancer cells with the goal that targeted delivery should increase the therapeutic window. However, target expression is not exclusive to cancers cells and the inherent properties of biologics distribution and catabolism narrow the therapeutic window. To achieve a meaningful therapeutic window an optimal combination of scaffold, target, toxin, type of cancer have to be carefully selected. Systems Pharmacology can help to identify the optimal compound design and eliminate many of the inferior options.

 

Nanobodies

 

Fab fragments

 

PEGylated biotherapeutics

 

Cell based therapies

 

siRNA